• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

半监督混合多源可交换性模型,用于在临床试验中利用真实世界数据。

Semi-supervised mixture multi-source exchangeability model for leveraging real-world data in clinical trials.

机构信息

Division of Biostatistics, University of Minnesota, Minneapolis, MN, 55414, USA.

Cooper Medical School of Rowan University and Medicine, Division of Infectious Diseases, Cooper University Hospital, Camden, New Jersey, 08103, USA.

出版信息

Biostatistics. 2024 Jul 1;25(3):617-632. doi: 10.1093/biostatistics/kxad024.

DOI:10.1093/biostatistics/kxad024
PMID:37697901
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11247180/
Abstract

The traditional trial paradigm is often criticized as being slow, inefficient, and costly. Statistical approaches that leverage external trial data have emerged to make trials more efficient by augmenting the sample size. However, these approaches assume that external data are from previously conducted trials, leaving a rich source of untapped real-world data (RWD) that cannot yet be effectively leveraged. We propose a semi-supervised mixture (SS-MIX) multisource exchangeability model (MEM); a flexible, two-step Bayesian approach for incorporating RWD into randomized controlled trial analyses. The first step is a SS-MIX model on a modified propensity score and the second step is a MEM. The first step targets a representative subgroup of individuals from the trial population and the second step avoids borrowing when there are substantial differences in outcomes among the trial sample and the representative observational sample. When comparing the proposed approach to competing borrowing approaches in a simulation study, we find that our approach borrows efficiently when the trial and RWD are consistent, while mitigating bias when the trial and external data differ on either measured or unmeasured covariates. We illustrate the proposed approach with an application to a randomized controlled trial investigating intravenous hyperimmune immunoglobulin in hospitalized patients with influenza, while leveraging data from an external observational study to supplement a subgroup analysis by influenza subtype.

摘要

传统的试验范式通常被批评为缓慢、低效和昂贵。利用外部试验数据的统计方法已经出现,通过增加样本量来提高试验效率。然而,这些方法假设外部数据来自以前进行的试验,留下了丰富的尚未有效利用的真实世界数据(RWD)。我们提出了一种半监督混合(SS-MIX)多源可交换性模型(MEM);一种灵活的两步贝叶斯方法,用于将 RWD 纳入随机对照试验分析。第一步是在修改后的倾向评分上进行 SS-MIX 模型,第二步是 MEM。第一步针对试验人群中的代表性亚组,第二步在试验样本和代表性观察性样本之间的结果存在实质性差异时避免借用。在一项模拟研究中,我们将提出的方法与竞争借用方法进行比较,发现当试验和 RWD 一致时,我们的方法可以有效地借用,而当试验和外部数据在测量或未测量协变量上存在差异时,可以减轻偏差。我们通过应用于一项静脉内高免疫球蛋白免疫球蛋白治疗住院流感患者的随机对照试验来说明该方法,同时利用外部观察性研究的数据来补充流感亚型的亚组分析。

相似文献

1
Semi-supervised mixture multi-source exchangeability model for leveraging real-world data in clinical trials.半监督混合多源可交换性模型,用于在临床试验中利用真实世界数据。
Biostatistics. 2024 Jul 1;25(3):617-632. doi: 10.1093/biostatistics/kxad024.
2
Optimal timing for an accelerated interim futility analysis incorporating real world data.纳入真实世界数据的加速期中无效性分析的最佳时机。
Contemp Clin Trials. 2024 May;140:107489. doi: 10.1016/j.cct.2024.107489. Epub 2024 Mar 8.
3
A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling.基于多源可交换性建模的贝叶斯平台试验设计与混合对照。
Stat Med. 2024 May 30;43(12):2439-2451. doi: 10.1002/sim.10077. Epub 2024 Apr 9.
4
Propensity score weighted multi-source exchangeability models for incorporating external control data in randomized clinical trials.倾向评分加权多源可交换性模型在随机临床试验中纳入外部对照数据。
Stat Med. 2024 Sep 10;43(20):3815-3829. doi: 10.1002/sim.10158. Epub 2024 Jun 24.
5
A Bayesian nonparametric causal inference model for synthesizing randomized clinical trial and real-world evidence.贝叶斯非参数因果推理模型,用于综合随机临床试验和真实世界证据。
Stat Med. 2019 Jun 30;38(14):2573-2588. doi: 10.1002/sim.8134. Epub 2019 Mar 18.
6
A flexible Bayesian framework for individualized inference via adaptive borrowing.一种通过自适应借用进行个体化推理的灵活贝叶斯框架。
Biostatistics. 2023 Jul 14;24(3):669-685. doi: 10.1093/biostatistics/kxab051.
7
Bayesian hierarchical modeling based on multisource exchangeability.基于多源可交换性的贝叶斯层次建模。
Biostatistics. 2018 Apr 1;19(2):169-184. doi: 10.1093/biostatistics/kxx031.
8
Propensity score-integrated composite likelihood approach for augmenting the control arm of a randomized controlled trial by incorporating real-world data.倾向评分整合复合似然方法在随机对照试验中纳入真实世界数据以增强对照臂。
J Biopharm Stat. 2020 May 3;30(3):508-520. doi: 10.1080/10543406.2020.1730877.
9
Bayesian Divide-and-Conquer Propensity Score Based Approaches for Leveraging Real World Data in Single Arm Clinical Trials.基于贝叶斯分而治之倾向评分法的单臂临床试验真实世界数据利用方法。
J Biopharm Stat. 2022 Jan 2;32(1):75-89. doi: 10.1080/10543406.2021.2011904. Epub 2022 Jan 29.
10
Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.利用历史数据促进肿瘤学开发项目:2 个 2 期贝叶斯增强控制试验设计案例研究。
Pharm Stat. 2020 May;19(3):276-290. doi: 10.1002/pst.1990. Epub 2020 Jan 5.

本文引用的文献

1
Robust Adaptive Incorporation of Historical Control Data in a Randomized Trial of External Cooling to Treat Septic Shock.在一项关于外部冷却治疗感染性休克的随机试验中稳健自适应纳入历史对照数据
Bayesian Anal. 2021 Sep;16(3):825-844. doi: 10.1214/20-ba1229. Epub 2020 Jul 31.
2
Calibrated dynamic borrowing using capping priors.使用封顶先验进行校准的动态借用。
J Biopharm Stat. 2021 Nov 2;31(6):852-867. doi: 10.1080/10543406.2021.1998100. Epub 2022 Feb 7.
3
Borrowing from supplemental sources to estimate causal effects from a primary data source.从补充资料中借用数据来估计原始资料的因果效应。
Stat Med. 2021 Oct 30;40(24):5115-5130. doi: 10.1002/sim.9114. Epub 2021 Jun 22.
4
Propensity score-integrated composite likelihood approach for augmenting the control arm of a randomized controlled trial by incorporating real-world data.倾向评分整合复合似然方法在随机对照试验中纳入真实世界数据以增强对照臂。
J Biopharm Stat. 2020 May 3;30(3):508-520. doi: 10.1080/10543406.2020.1730877.
5
Extending inferences from a randomized trial to a new target population.将随机试验的推断扩展到新的目标人群。
Stat Med. 2020 Jun 30;39(14):1999-2014. doi: 10.1002/sim.8426. Epub 2020 Apr 6.
6
Dynamic borrowing in the presence of treatment effect heterogeneity.存在治疗效果异质性时的动态借用。
Biostatistics. 2021 Oct 13;22(4):789-804. doi: 10.1093/biostatistics/kxz066.
7
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.抗流感病毒高免静脉用免疫球蛋白治疗成人甲型或乙型流感感染(FLU-IVIG):一项双盲、随机、安慰剂对照试验。
Lancet Respir Med. 2019 Nov;7(11):951-963. doi: 10.1016/S2213-2600(19)30253-X. Epub 2019 Sep 30.
8
Propensity score-integrated power prior approach for incorporating real-world evidence in single-arm clinical studies.倾向评分整合的先验功率方法,用于在单臂临床研究中纳入真实世界证据。
J Biopharm Stat. 2019;29(5):731-748. doi: 10.1080/10543406.2019.1657133. Epub 2019 Sep 17.
9
Generalizability of randomized trial results to target populations: Design and analysis possibilities.随机试验结果对目标人群的可推广性:设计与分析的可能性
Res Soc Work Pract. 2018 Jul;28(5):532-537. doi: 10.1177/1049731517720730. Epub 2017 Jul 27.
10
Randomised controlled trials - the gold standard for effectiveness research: Study design: randomised controlled trials.随机对照试验——有效性研究的金标准:研究设计:随机对照试验
BJOG. 2018 Dec;125(13):1716. doi: 10.1111/1471-0528.15199. Epub 2018 Jun 19.